The Europe Deep Brain Stimulation Devices Market is expected to witness market growth of 15.7% CAGR during the forecast period (2019-2025).
Each year over 50 000 Europeans are diagnosed with Parkinson's disease. In addition to this, European scientists have developed a method for delivering a patient-specific brain stimulation therapy. Deep brain stimulation (DBS) is an approved treatment for essential tremor, dystonia and Parkinson's disease. A research program of the European Union called IMPACT is making strides in enhancing and individualizing the deep brain stimulation (DBS) for Parkinson's disease.
Deep brain stimulation (DBS) is a medical technique used to treat many crippling neurological disorders such as Parkinson's Disease (PD) severe motor symptoms such as bradykinesia, stiffness, critical tremor, psychological problems (obsessive-compulsive disorder), and slow motion. Deep brain stimulation therapy is typically prescribed for patients who for at least five years have not reacted to medications. Electrodes are implanted in certain areas of affected brain in this treatment which generates electrical impulses that control abnormal impulses.
Based on Applications, the market is segmented into Parkinson's disease, Epilepsy, Essential Tremor, Dystonia, Obsessive Compulsive Disorder and Other Applications. Based on End User, the market is segmented into Neurological Clinics, Ambulatory Surgical Centers, Hospital and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Functional Neuromodulation, Ltd., Beijing PINS Medical Co., Ltd., NeuroPace, Inc., Nevro Corporation, Neuronetics, Inc., and Fisher Wallace Laboratories, Inc.
Scope of the Study
Market Segmentation:
By Applications
By End User
By Country
Companies Profiled
Unique Offerings from the Publisher
Each year over 50 000 Europeans are diagnosed with Parkinson's disease. In addition to this, European scientists have developed a method for delivering a patient-specific brain stimulation therapy. Deep brain stimulation (DBS) is an approved treatment for essential tremor, dystonia and Parkinson's disease. A research program of the European Union called IMPACT is making strides in enhancing and individualizing the deep brain stimulation (DBS) for Parkinson's disease.
Deep brain stimulation (DBS) is a medical technique used to treat many crippling neurological disorders such as Parkinson's Disease (PD) severe motor symptoms such as bradykinesia, stiffness, critical tremor, psychological problems (obsessive-compulsive disorder), and slow motion. Deep brain stimulation therapy is typically prescribed for patients who for at least five years have not reacted to medications. Electrodes are implanted in certain areas of affected brain in this treatment which generates electrical impulses that control abnormal impulses.
Based on Applications, the market is segmented into Parkinson's disease, Epilepsy, Essential Tremor, Dystonia, Obsessive Compulsive Disorder and Other Applications. Based on End User, the market is segmented into Neurological Clinics, Ambulatory Surgical Centers, Hospital and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Functional Neuromodulation, Ltd., Beijing PINS Medical Co., Ltd., NeuroPace, Inc., Nevro Corporation, Neuronetics, Inc., and Fisher Wallace Laboratories, Inc.
Scope of the Study
Market Segmentation:
By Applications
- Parkinson's disease
- Epilepsy
- Essential Tremor
- Dystonia
- Obsessive Compulsive Disorder
- Other Applications
By End User
- Neurological Clinics
- Ambulatory Surgical Centers
- Hospital
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- Aleva Neurotherapeutics SA
- Functional Neuromodulation, Ltd.
- Beijing PINS Medical Co., Ltd.
- NeuroPace, Inc.
- Nevro Corporation
- Neuronetics, Inc.
- Fisher Wallace Laboratories, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Deep Brain Stimulation Devices Market by Applications
Chapter 4. Europe Deep Brain Stimulation Devices Market by End Users
Chapter 5. Europe Deep Brain Stimulation Devices Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Medtronic PLC
- Boston Scientific Corporation
- Aleva Neurotherapeutics SA
- Functional Neuromodulation, Ltd.
- Beijing PINS Medical Co., Ltd.
- NeuroPace, Inc.
- Nevro Corporation
- Neuronetics, Inc.
- Fisher Wallace Laboratories, Inc.
Methodology
LOADING...
